Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Experts aren’t really on board with taking these new, buzzy, multi-ingredient supplements that claim to help with insulin resistance. However, a few vitamin and mineral supplements do have some ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

Join a real-time written chat with WSJ’s Bradley Olson on Monday, March 24, from 3 p.m. to 4 p.m. ET. WSJ subscribers can ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...

GLP-1 (glucagon-like peptide) medications, such as Ozempic and Wegovy, have seen a surge in popularity over the past few ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...

Early adopters of GLP-1 drugs have now lost the weight and are beginning to transition off them. How can F&B support the ...

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

There are so many false promises online when it comes to losing weight. Here are my top weight loss technologies that ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

New weight loss drugs like Ozempic and Wegovy help suppress appetite, leading to significant weight loss, but they come with ...